Simris Alg AB (publ) (SIMRIS-B.ST)
SEK 0.1
(-10.77%)
SEK 0.1
(-10.77%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -22.36 Million SEK | -28.65% |
| 2022 | -18 Million SEK | 17.88% |
| 2021 | -24.8 Million SEK | -6.1% |
| 2020 | -20.66 Million SEK | 3.88% |
| 2019 | -21.49 Million SEK | -12.02% |
| 2018 | -19.19 Million SEK | -0.33% |
| 2017 | -19.12 Million SEK | -11.46% |
| 2016 | -17.16 Million SEK | -58.42% |
| 2015 | -10.83 Million SEK | -35.89% |
| 2014 | -7.97 Million SEK | -103.98% |
| 2013 | -3.9 Million SEK | -38.46% |
| 2012 | -2.82 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -5.32 Million SEK | 1.44% |
| 2024 Q2 | -6.24 Million SEK | -14.87% |
| 2023 Q1 | -5.99 Million SEK | 26.86% |
| 2023 Q3 | -4.52 Million SEK | 29.73% |
| 2023 Q2 | -6.43 Million SEK | -7.33% |
| 2023 FY | - SEK | -28.65% |
| 2023 Q4 | -5.53 Million SEK | -22.28% |
| 2022 FY | - SEK | 17.88% |
| 2022 Q2 | -4.05 Million SEK | -18.42% |
| 2022 Q3 | -4.47 Million SEK | -10.4% |
| 2022 Q4 | -8.2 Million SEK | -83.45% |
| 2022 Q1 | -3.42 Million SEK | -72.29% |
| 2021 Q3 | -7.14 Million SEK | -17.28% |
| 2021 Q1 | -6.69 Million SEK | -3.81% |
| 2021 Q2 | -6.09 Million SEK | 8.98% |
| 2021 FY | - SEK | -6.1% |
| 2021 Q4 | -1.98 Million SEK | 72.23% |
| 2020 Q1 | -6.08 Million SEK | -13.34% |
| 2020 FY | - SEK | 3.88% |
| 2020 Q3 | -3.8 Million SEK | 12.02% |
| 2020 Q2 | -4.32 Million SEK | 28.88% |
| 2020 Q4 | -6.45 Million SEK | -69.47% |
| 2019 Q4 | -5.36 Million SEK | 4.21% |
| 2019 Q3 | -5.6 Million SEK | 11.19% |
| 2019 Q2 | -6.3 Million SEK | -49.54% |
| 2019 Q1 | -4.21 Million SEK | 28.5% |
| 2019 FY | - SEK | -12.02% |
| 2018 Q1 | -4.7 Million SEK | 14.97% |
| 2018 Q3 | -4.62 Million SEK | -16.87% |
| 2018 Q4 | -5.9 Million SEK | -27.51% |
| 2018 FY | - SEK | -0.33% |
| 2018 Q2 | -3.96 Million SEK | 15.8% |
| 2017 FY | - SEK | -11.46% |
| 2017 Q4 | -5.53 Million SEK | -14.85% |
| 2017 Q3 | -4.81 Million SEK | -17.04% |
| 2017 Q2 | -4.11 Million SEK | 11.83% |
| 2017 Q1 | -4.66 Million SEK | 19.03% |
| 2016 Q1 | -4.4 Million SEK | -51.69% |
| 2016 Q2 | -4.09 Million SEK | 7.06% |
| 2016 Q3 | -2.9 Million SEK | 28.97% |
| 2016 FY | - SEK | -58.42% |
| 2016 Q4 | -5.76 Million SEK | -98.33% |
| 2015 Q2 | -3.45 Million SEK | -34.13% |
| 2015 Q3 | -1.89 Million SEK | 45.23% |
| 2015 Q4 | -2.9 Million SEK | -53.22% |
| 2015 Q1 | -2.57 Million SEK | 0.0% |
| 2015 FY | - SEK | -35.89% |
| 2014 FY | - SEK | -103.98% |
| 2013 FY | - SEK | -38.46% |
| 2012 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 92.956% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 92.071% |
| Xintela AB (publ) | -53.47 Million SEK | 58.177% |
| Active Biotech AB (publ) | -43.88 Million SEK | 49.044% |
| Amniotics AB (publ) | -27.14 Million SEK | 17.61% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -57.298% |
| BioArctic AB (publ) | 275.38 Million SEK | 108.121% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 93.92% |
| Camurus AB (publ) | 562.54 Million SEK | 103.975% |
| Cantargia AB (publ) | -284.31 Million SEK | 92.134% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -14.219% |
| CombiGene AB (publ) | -35.33 Million SEK | 36.713% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 84.123% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -30.896% |
| Genovis AB (publ.) | 64.57 Million SEK | 134.633% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 80.538% |
| Mendus AB (publ) | -97.84 Million SEK | 77.145% |
| Isofol Medical AB (publ) | -37.02 Million SEK | 39.599% |
| Intervacc AB (publ) | -68.98 Million SEK | 67.58% |
| Kancera AB (publ) | -61.88 Million SEK | 63.866% |
| Karolinska Development AB (publ) | -26.78 Million SEK | 16.503% |
| LIDDS AB (publ) | -39.67 Million SEK | 43.627% |
| Lipum AB (publ) | -37.11 Million SEK | 39.753% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -84.757% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 171.211% |
| NextCell Pharma AB | -40.98 Million SEK | 45.436% |
| OncoZenge AB (publ) | 7.26 Million SEK | 407.776% |
| Saniona AB (publ) | -69.69 Million SEK | 67.913% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 86.831% |
| Ziccum AB (publ) | -20.34 Million SEK | -9.935% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 1118250.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 90.589% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -975.144% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -66.503% |
| Corline Biomedical AB | -1.69 Million SEK | -1222.472% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 87.098% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 59.196% |
| Aptahem AB (publ) | -10 Million SEK | -123.424% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 293.636% |
| Fluicell AB (publ) | -25.91 Million SEK | 13.703% |
| Biovica International AB (publ) | -119.5 Million SEK | 81.287% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 47.037% |
| AcouSort AB (publ) | -16.7 Million SEK | -33.886% |
| Abliva AB (publ) | -93.6 Million SEK | 76.11% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 92.992% |
| 2cureX AB (publ) | -35.13 Million SEK | 36.353% |
| I-Tech AB | 30.34 Million SEK | 173.696% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 96.87% |
| Cyxone AB (publ) | -20.41 Million SEK | -9.547% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 78.172% |
| Biosergen AB | 228 Thousand SEK | 9908.333% |
| Nanologica AB (publ) | -62.11 Million SEK | 64.0% |
| SynAct Pharma AB | -222.7 Million SEK | 89.958% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 49.014% |
| BioInvent International AB (publ) | -312.7 Million SEK | 92.849% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 7327.557% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 53346.506% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 90.345% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -153.765% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 79.4% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -94.986% |